INTRODUCTION: Recommended treatment for early-stage NSCLC is complete surgical resection, with adjuvant chemotherapy in stage II–IIIA and select stage IB; however, approximately 30–70% of patients will experience disease recurrence within 5 years post-surgery. Osimertinib is an epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) approved for adjuvant treatment of resected stage IB–IIIA EGFR-mutated (EGFRm) NSCLC based on results from the Phase III ADAURA trial. This retrospective global chart review of resectable NSCLC aimed to better understand real-world EGFRm testing and treatment practices. Here, we report final data from UK patients across three sites.
METHODS: Adults with completely resected stage IA–IIIA NSCLC diagnosed between 1 January, 2014 and 31 December, 2017 and available EGFR test results were included and followed to at least 31 December, 2020. Primary objectives included assessment of EGFRm frequency, treatment and testing patterns.
RESULTS: Of 134 UK patients, 19/134 (14%) had EGFRm NSCLC. Median age was 70 years (range: 44–92); of those with data available, most were female (70/134, 52%), White (84/88, 95%) and former smokers (78/120, 65%). Overall, 29/134 (22%) had stage IA, 25 (19%) IB, 34 (25%) IIA, 20 (15%) IIB, and 26 (19%) IIIA disease at diagnosis. Median turnaround time for EGFR test result was 19 days (range: 1–50). Median follow-up from diagnosis was 49 months (interquartile range: 20–60). Most patients received no systemic treatment (82/134, 61%); 31/134 (23%) received adjuvant chemotherapy alone and 1 patient received neoadjuvant and adjuvant treatments. Salvage/post-recurrence treatment was received by 20/134 (15%) patients: 11/20 chemotherapy, 10/20 immunotherapy and 4/20 targeted therapy.
CONCLUSIONS: In this real-world study of UK patients with resected early-stage NSCLC, 14% had EGFRm. Median turnaround time to EGFR test result was 19 days. Improvements in turnaround time for molecular testing will help to identify patients for optimal treatment.
